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What is the proper control group for a fibromyalgia
study? Comment on the article by Loggia et al
To the Editor:
The recent study by Loggia et al (1) has design prob-
lems that may negate the authors’ conclusions. First, they
chose a control group composed of healthy pain-free individ-
uals rather than a group with chronic pain of peripheral tissue
origin. As in several other studies of pain processing (2–5), use
of a normal control group eliminates, at the design level, the
possibility of determining whether brain circuitry alterations in
patients labeled as having fibromyalgia differ from those in
patients with pain-causing disorders known to be peripheral
and nociceptive.
Second, the pain-free control group differed from the
study group not only in the presence or absence of chronic pain
but also (and markedly so) in indices of depression and fatigue,
as shown in Table 1 (1). These differences may add important
confounders to cerebral imaging (6,7). Unless such variables
are matched in the control group, they may introduce indeter-
minacy into the interpretation of imaging and psychophysical
findings. The proper controls thus should be patients with
chronic peripheral pain accompanied by depression.
Furthermore, the authors could have extracted a mod-
icum of information, even in the absence of a relevant control
group, by displaying a severity-related gradation in the results.
The large standard deviations shown in Table 1 suggest that
some patients had 6-fold higher scores than others for pain
intensity and the number of pain sites. The decision by the
Loggia group not to sort the study group results according to
pain level may mask discovery of relevant findings such as
whether or not there was an ascending response to increased
baseline pain or a threshold below which differences were not
present.
In summary, the authors’ finding of differences from
normal controls cannot demonstrate anything unique or aber-
rant about the study group’s pain-processing brain circuitry,
nor can the findings be seen as supportive of “augmented
central processing,” the primary axiom of the fibromyalgia
hypothesis. Without the discovery of distinct differences be-
tween patients and carefully matched control subjects with
underlying nociceptive peripheral chronic pain, speculative
claims of brain circuitry disruption that is unique to the group
with fibromyalgia cannot be substantiated.
James H. Lampman, MD
Kent, CT
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Reply
To the Editor:
We very much appreciate the perspective of Dr.
Lampman regarding our recent study. In biomedicine, and
indeed in most experimental sciences, the choice of a proper
control group (or condition) is a fundamental step to ensure
that the conclusions drawn from an experiment have validity
and are meaningful.
What is a proper control in a fibromyalgia study? The
answer is, of course, “it depends on what question is being
investigated.” In our recent study, we used functional magnetic
resonance imaging to test the hypothesis that patients with
fibromyalgia demonstrate altered brain activity during antici-
pation of both pain and pain relief. For this experiment, we
elected to compare patients with fibromyalgia with pain-free
healthy volunteers rather than a disease control group (such as
a group with a different pain disorder). Dr. Lampman criti-
cized this choice, suggesting that our approach prevented us
from assessing whether the observed alterations in brain
activity are unique to fibromyalgia (or could be observed in
other pain conditions, such as “pain-causing disorders known
to be peripheral and nociceptive”).
We would like to point out that the purpose of our
study was never to identify brain alterations specific to fi-
bromyalgia, and we never made such a claim in our report.
Instead, our aim was to demonstrate the presence of altera-
tions in brain activity in patients with fibromyalgia compared
with healthy, pain-free individuals (which may or may not
be unique to this particular chronic pain disorder). For this
purpose, we believe that the choice of a demographically
matched control group of healthy volunteers was entirely
appropriate. Future experiments will need to assess whether a
similar paradigm applied to the study of other chronic pain
disorders, with greater or lesser peripheral or nociceptive pain
components, does or does not yield similar results. Indeed, a
newly proposed pain taxonomy (1) provides several categories
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of chronic pain conditions, and it would certainly be instructive
to compare patients with fibromyalgia and samples of patients
with, for instance, localized peripheral or central neuropathic
pain conditions, visceral pain syndromes, cancer-related pain,
or regional musculoskeletal pain disorders.
We certainly agree that our fibromyalgia and control
groups differed not only in the presence or absence of wide-
spread pain but also in terms of other factors (e.g., negative
affect, fatigue). These differences, however, are truly reflective
of the multisymptom nature of fibromyalgia, and we do not
believe that they are confounders in our experimental design.
Symptoms such as fatigue, anxiety, depression, and sleep or
cognitive deficits are highly comorbid with, and therefore an
integral part of, fibromyalgia (2,3). Attempting to identify a
control group that is perfectly matched to the fibromyalgia
group, except for the presence of pain, would be extremely
difficult and would also generate results that are not reflective
of the full spectrum of the fibromyalgia disorder. Nonetheless,
we agree that it is important to try to determine whether any
specific symptoms reported by patients with fibromyalgia con-
tribute more than others to explain any differences in the
observed brain processing. Such an analysis requires a multi-
variate statistical approach in a large patient sample, and we
hope that future analyses will in fact be able to tease out the
distinct contributions of different variables to the neuroimag-
ing alterations observed in previous studies.
Finally, regarding the wide range in the scoring of
clinical pain intensity and unpleasantness reported by our
patients, we believe that this is endemic to the fibromyalgia
population and may be advantageous for dynamic range in
further statistical analyses, something we will take full advan-
tage of in future analyses exploring the relationship between
pain levels and brain activity.
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Standardized incidence ratios for gout: comment on
the article by Krishnan
To the Editor:
I read with great interest the recent article by Krishnan
on the incidence of gout (1). Dr. Krishnan reports that,
compared with the rate of incidence of gout in the Rochester
Epidemiology Project (2), the age-standardized incidence ratio
(SIR) was 745 (95% confidence interval [95% CI] 714–778)
among participants in the Multiple Risk Factor Intervention
Trial (MRFIT). Additionally, the SIRs were 581 (95% CI
540–623), 792 (95% CI 788–796), and 1,759 (95% CI 1,479–
2,122) among participants in the MRFIT with estimated
glomerular filtration rates (GFRs) of 90 ml/minute/1.73 m2,
60–89 ml/minute/1.73 m2, and 60 ml/minute/1.73 m2, respec-
tively. Since participants in the MRFIT are at increased risk of
gout (overweight/obese, hypertension, etc.), one would expect
that the incidence of gout in this population should be higher
than that among the participants in the Rochester Epidemiol-
ogy Project; however, these SIRs, which refer to a 581–1,759
times higher risk between the 2 cohorts, seem too large.
To illustrate this point, I have calculated the highest
possible SIR of incident gout between the 2 cohorts using the
formula described by Breslow and Day (3). First, I estimated
the lowest possible expected number of gout cases in the
MRFIT study by multiplying the incidence rate among subjects
in the youngest overlapping age group (30–39 years) from the
Rochester Epidemiology Project by the total number of
person-years from the MRFIT study (i.e., 0.6/1,000 person-
years 76,602 person-years 46 cases). Then I divided the 46
expected gout cases by the total number of observed gout cases
in the MRFIT study (i.e., 722 cases). In this way I calculated
the highest possible value of the SIR as 15.7. I found that even
this maximum possible SIR value is substantially smaller than
the rates reported in the article. By the same approach, the
SIRs were 11.2, 17.6, and 45.3 among the participants with
estimated GFRs of 90 ml/minute/1.73 m2, 60–89 ml/minute/
1.73 m2, and60 ml/minute/1.73 m2, respectively–also smaller,
by similar magnitudes, than the corresponding estimates re-
ported by Dr. Krishnan (i.e., 581, 792, and 1,759).
In conclusion, while my results also show that inci-
dence rates of gout among participants in the MRFIT are
higher than those in the Rochester Epidemiology Project and
that those with severe kidney disease are at increased risk of
gout, my analysis indicates that the magnitude of the SIR
estimates should be substantially smaller than the findings
reported by Dr. Krishnan.
Supported by the Boston University Hing Wah Cheung Fellowship Fund.
Na Lu, BM
Boston University School of Public Health
Boston, MA
1. Krishnan E. Chronic kidney disease and the risk of incident gout
among middle-aged men: a seven-year prospective observational
study. Arthritis Rheum 2013;65:3271–8.
2. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE.
Epidemiology of gout: is the incidence rising? J Rheumatol 2002;
29:2403–6.
3. Breslow NE, Day NE. Statistical methods in cancer research. Vol.
LETTERS 1685
